INM

InMed Pharmaceuticals Inc. (INM) Economic Moat Analysis (2026)

Invetso Score: 3.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 4.2 (Moderate)

INM appears to rely on specialized content or information assets, but the provided metrics do not show durable excess returns that would indicate strong pricing power versus peers.

Negative TTM ROIC and ROCE suggest any proprietary asset base is not yet translating into superior economic value capture, which weakens evidence of a moat relative to better monetizing peers.

No 5-year margin or return history was provided, so there is insufficient evidence that intangible assets have compounded into a durable advantage over time.

Compared with stronger media, data, or information-service peers, the current evidence supports only a modest intangible-asset moat rather than a clearly differentiated one.

Switching Costs

Score:

The available financial metrics do not indicate customer lock-in, because negative ROIC and ROCE imply the business is not retaining enough value to demonstrate sticky, high-retention relationships versus peers.

A negative cash conversion cycle can reflect favorable working-capital dynamics, but it does not by itself prove that customers face meaningful switching friction or contractual dependence.

No disclosure was provided on renewal rates, embedded workflows, or integration depth, so there is no direct evidence of switching costs that would protect margins over 5–10 years.

Relative to software or data peers with high renewal visibility and embedded usage, INM currently shows weak evidence of switching-based durability.

Network Effects

Score:

The provided data do not show user-to-user, buyer-to-seller, or data-network feedback loops that would make the product more valuable as adoption rises.

Negative returns on capital argue against a self-reinforcing ecosystem that is converting scale into stronger monetization than peers.

No evidence was provided of platform density, marketplace liquidity, or audience/network compounding, so network effects cannot be credited materially.

Compared with peer businesses that benefit from clear network flywheels, INM appears to have little observable network-effect protection.

Cost Advantage

Score:

Asset turnover of 0.44x suggests the asset base is not being used with exceptional efficiency, which weakens the case for a structural cost advantage versus peers.

Negative ROIC and ROCE indicate the company is not currently converting operations into superior unit economics, so any cost edge is not visible in the reported metrics.

No evidence was provided of lower input costs, scale purchasing power, or process advantages that would sustain margin superiority over a 5–10 year horizon.

Relative to peers with demonstrable operating leverage or superior productivity, INM does not currently show a durable cost advantage.

Efficient Scale

Score:

If INM serves a niche market, efficient scale could exist, but the provided data do not confirm that the market is small enough to support durable oligopoly economics.

Negative capital returns suggest the company is not yet extracting the kind of scarcity rents that typically accompany efficient-scale advantages.

No evidence was provided of regulated scarcity, exclusive distribution, or capacity constraints that would limit peer entry and protect returns.

Compared with peers in concentrated markets, INM shows only limited signs of efficient scale and no clear proof of durable structural protection.

Overall Score

Score:

INM’s moat appears weak overall versus peers because the provided metrics show negative capital returns and no direct evidence of switching costs, network effects, or durable cost advantage; any intangible or niche-scale benefits are not yet translating into sustained pricing power or retention.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on InMed Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →